Previous close | 28.600 |
Open | 28.600 |
Bid | 27.550 x N/A |
Ask | 27.650 x N/A |
Day's range | 27.500 - 29.000 |
52-week range | 22.100 - 52.550 |
Volume | |
Avg. volume | 1,682,332 |
Market cap | 42.129B |
Beta (5Y monthly) | 0.73 |
PE ratio (TTM) | 13.21 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.62 (2.26%) |
Ex-dividend date | 07 Jun 2024 |
1y target est | N/A |
Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2023 (the "Reporting Period").